Quarterly report pursuant to Section 13 or 15(d)

NATURE OF BUSINESS AND ORGANIZATION (Details)

v3.24.3
NATURE OF BUSINESS AND ORGANIZATION (Details)
 1 Months Ended 3 Months Ended 6 Months Ended
Sep. 30, 2022
USD ($)
Jun. 30, 2024
USD ($)
Mar. 31, 2024
USD ($)
Jun. 30, 2023
USD ($)
Mar. 31, 2023
USD ($)
Jun. 30, 2024
USD ($)
segment
Jun. 30, 2023
USD ($)
Dec. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
Accumulated deficit   $ 230,322,371       $ 230,322,371     $ 202,761,017
Net loss   (919,371) $ (26,641,983) $ (10,178,640) $ (7,190,470) (27,561,355) $ (17,369,110)    
Unrestricted cash and cash equivalents   25,868,907       $ 25,868,907     9,564,988
Number of Reportable Segments | segment           1      
Fixed asset impairment charges           $ 0 0    
Uninsured cash balances   25,422,000       25,422,000     $ 9,123,000
Government Assistance, Statement of Income or Comprehensive Income [Extensible Enumeration] Costs and Expenses                
Subsequent event                  
Unrestricted cash and cash equivalents               $ 34,300,000  
Cancer treatment research award through the National Cancer Institute (NCI)                  
Government Assistance Amount Cumulative   $ 2,000,000.0       $ 2,000,000.0      
Government Assistance Transaction Duration           3 years      
Grant received $ 1,980,000                
Reduction in research and development           $ 465,000 $ 647,000    
Leasehold improvements                  
Property and equipment useful lives   64 months       64 months      
Minimum                  
Property and equipment useful lives   3 years       3 years      
Share-based compensation expiration period           12 months      
Maximum                  
Property and equipment useful lives   10 years       10 years      
Share-based compensation expiration period           3 years